A Phase 4, Single-Arm, Open-Label Study describing the safety and immunogenicity of Bexsero in healthy subjects aged 12 years to <19 years.
Phase of Trial: Phase IV
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 02 Apr 2016 Status changed from recruiting to completed, according to European Clinical Trials Database record.
- 10 Feb 2015 New trial record